In terms of regulation 5(4) of the Control of Concentrations Regulations, 2002 published in Legal Notice 294 of 2002, the Director General of the Office for Competition notifies for general information that a notification of a concentration between L1 Health GP S.À.R.L. (Luxembourg) and Emma Healthcare Holdings Ltd (Limassol, Cyprus) was filed on Friday, 23 December 2022.
L1 Health GP S.À.R.L. currently jointly controls Emma Healthcare Holdings Ltd along with certain funds affiliated with Blantyre Capital Limited. The nature of the concentration is the acquisition by L1 Health GP S.À.R.L. of the shares held by these funds in Emma Healthcare Holdings Ltd. As a result of this concentration, L1 Health GP S.À.R.L. will hold, in effect, all of the shareholding in Emma Healthcare Holdings Ltd.
L1 Health GP S.À.R.L. is part of the LetterOne Investment Holdings group. LetterOne Investment Holdings is an investment holding company that invests primarily in healthcare, telecom and technology, and retail sectors, and one of its companies, Holland & Barrett, has a franchisee that is present in Malta. L1 Health GP S.À.R.L. has also invested in companies in the pet health care services sector. Emma Healthcare Holdings Ltd, through its subsidiary Remedica, develops, produces, distributes, and sells pharmaceutical products such as various therapeutic categories including antineoplastic agents, antivirals, cardiovascular, central nervous system agents, gastrointestinal agents, respiratory tract agents, dermatological agents, and anti-infective products. It is also active in the food supplements industry through another subsidiary, Sun Wave Pharma. Emma Healthcare Holdings Ltd is currently present in Malta through activities of the Remedica group.
The Director General of the Office for Competition invites interested third parties to submit their written objections on this notified concentration within seven days following publication of this notice at the following address: